CHCWM – Cancer & Hematology Centers of West Michigan

TTX-080-001 (Tizona)

Description:   A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies.

Mechanism of Action:  TTX-080 (anti HLA-G antibody- myeloid checkpoint inhibitor) monotherapy, or with Pembrolizumab or with Cetuximab

Target Patient Population:   Head and Neck (≤2 prior lines), CRC (≤3 prior lines), NSCLC (≤3 prior lines),Triple Negative Breast (≤2 prior lines)

Study Design:  Drug is given IV Day 1, 15 of first 28 day cycle, then day 1 of subsequent cycles